

CITATION REPORT

List of articles citing

Improving multiple sclerosis management and collecting safety information in the real world: the MSDS3D software approach

DOI: 10.1080/14740338.2018.1437144

Expert Opinion on Drug Safety, 2018, 17, 369-378.

Source: <https://exaly.com/paper-pdf/69028954/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
32	Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up. <i>Frontiers in Neurology</i> , 2018 , 9, 1071	4.1	23
31	Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients. <i>Frontiers in Immunology</i> , 2018 , 9, 2669	8.4	23
30	Dem MS-Phänotyp auf der Spur. <i>Der Neurologe Und Psychiater</i> , 2019 , 20, 33-36	0	2
29	Review: Patient-reported outcomes in multiple sclerosis care. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 33, 61-66	4	47
28	Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6, e555	9.1	63
27	Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. <i>Frontiers in Neurology</i> , 2019 , 10, 253	4.1	12
26	Multiple sclerosis registries in Europe - An updated mapping survey. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 27, 171-178	4	33
25	The transitional phase of multiple sclerosis: The concept of PANGAEA 2.0 evolution study. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 46, 102523	4	2
24	The Dresden Protocol for Multidimensional Walking Assessment (DMWA) in Clinical Practice. <i>Frontiers in Neuroscience</i> , 2020 , 14, 582046	5.1	8
23	Der Patient als Experte. <i>Der Neurologe Und Psychiater</i> , 2020 , 21, 33-36	0	1
22	Data Collection in Multiple Sclerosis: The MSDS Approach. <i>Frontiers in Neurology</i> , 2020 , 11, 445	4.1	12
21	A Digital Patient Portal for Patients With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020 , 11, 400	4.1	13
20	Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol. <i>BMC Neurology</i> , 2020 , 20, 95	3.1	10
19	Standardization and digitization of clinical data in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2021 , 17, 119-125	15	3
18	Electronic Health Interventions in the Case of Multiple Sclerosis: From Theory to Practice. <i>Brain Sciences</i> , 2021 , 11,	3.4	11
17	Digital Twins for Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021 , 12, 669811	8.4	32
16	An ID-Associated Application to Facilitate Patient-Tailored Management of Multiple Sclerosis. <i>Brain Sciences</i> , 2021 , 11,	3.4	0

15	Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA. <i>JMIR Research Protocols</i> , 2020 , 9, e19598	2	9
14	Literatur. 2022 , 468-512		
13	Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA (Preprint).		
12	Digital Biomarkers in Multiple Sclerosis. <i>Brain Sciences</i> , 2021 , 11,	3-4	4
11	Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.. <i>Journal of Neurology</i> , 2022 , 1	5-5	3
10	Table_1.pdf. 2018 ,		
9	Data_Sheet_1.PDF. 2020 ,		
8	Data_Sheet_2.PDF. 2020 ,		
7	Data_Sheet_3.PDF. 2020 ,		
6	Data_Sheet_4.PDF. 2020 ,		
5	Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study. <i>Frontiers in Neurology</i> , 2022 , 13,	4-1	1
4	OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany. <i>Frontiers in Neurology</i> , 13,	4-1	0
3	Steigerung der Therapietreue durch niederschwellige Kontakte. 2022 , 41, 497-501		
2	Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description. 2022 , 13, 204062232211174		0
1	MSmonitor-plus program and video calling care (MPVC) for multidisciplinary care and self-management in multiple sclerosis: study protocol of a single-center randomized, parallel-group, open label, non-inferiority trial. 2022 , 22,		0